Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for IDEAYA Biosciences (IDYA) over the last 5 years, with Q3 2025 value amounting to $2.2 million.

  • IDEAYA Biosciences' Current Deferred Revenue changed N/A to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of $8.6 million for FY2022, which is 8577.5% down from last year.
  • As of Q3 2025, IDEAYA Biosciences' Current Deferred Revenue stood at $2.2 million.
  • Over the past 5 years, IDEAYA Biosciences' Current Deferred Revenue peaked at $77.6 million during Q1 2021, and registered a low of $1.4 million during Q3 2023.
  • Over the past 4 years, IDEAYA Biosciences' median Current Deferred Revenue value was $30.7 million (recorded in 2022), while the average stood at $33.5 million.
  • Per our database at Business Quant, IDEAYA Biosciences' Current Deferred Revenue tumbled by 2810.09% in 2021 and then plummeted by 9357.71% in 2023.
  • Quarter analysis of 4 years shows IDEAYA Biosciences' Current Deferred Revenue stood at $60.2 million in 2021, then crashed by 85.78% to $8.6 million in 2022, then plummeted by 83.2% to $1.4 million in 2023, then soared by 50.52% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $1.4 million for Q3 2023, and $2.8 million during Q2 2023.